Hi J8, all cohorts get the same dose of Cal-1, cohort 2 gets a low dose of busulfan (a type of chemotherapy) to cohort 3 gets a medium dose.
Obviously, it would be preferable if this wasn't necessary for the drug to work.
Cadence1, just to clarify BKIKF and BLT are the same company. Merck has sold it's RNAi assets to Alnylam.
